SATI.AQSE

Sativa Investments plc
Sativa Group PLC - Sativa’s joins the ACI toxicology study
25th September 2020, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0717A
Sativa Group PLC
25 September 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

Sativa Group Plc
("Sativa" or the "Company" or the "Group")

Sativa's joins the ACI toxicology study to further it's commitment to Novel Food compliance

25 September 2020

 

As part of the Sativa Group PLC's ongoing commitment to continually deliver the highest level of regulatory compliance and substantiate 'CBD you can trust', the Company has become a member of the Association for the Cannabinoid Industry (ACI) Novel Food consortium and it's landmark toxicology study, which will augment the submission of it's own Novel Food application dossier.

The toxicology study will provide safety data that is required for Novel Food dossiers validated by the FSA, and for products to remain available on the market after 31 March 2021.

Sativa and Stillcanna's team of scientists and quality/compliance professionals in the UK and Poland have worked with the ACI to ensure it's CBD products meet their rigorous quality management criteria.

As part of this regulatory process, the raw CBD ingredients and final products are tested by a leading third-party laboratory, and cultivation, extraction and manufacturing processes and standards are scrutinised, to ensure that Sativa is meeting safety and regulatory standards from seed through to shelf.

The Company is submitting its own novel food application for it's portfolio of products and brands, and on behalf of White Label customers.   

Henry Lees-Buckley, Chief Executive Office of Sativa, said: "At Sativa, producing the highest quality and compliant products is our number one objective! We welcome the FSA Novel Foods accreditation process and are very pleased to be associated with the ACI In our compliance efforts".

The directors of the Company accept responsibility for the contents of this announcement.

Enquiries:

Henry Lees-Buckley 

Chief Executive Officer

Sativa Group Plc

+44 (0) 20 7971 1255

enquiries@sativagroup.co.uk

www.sativagroup.co.uk

 

Joseph Colliver

Chief Financial Officer

Sativa Group Plc

+44 (0) 20 7971 1255

enquiries@sativagroup.co.uk

www.sativagroup.co.uk

 

AQSE Growth Market Corporate Adviser

Corporate Finance 

Guy Miller/Allie Feuerlein

Peterhouse Capital Limited

+44 (0) 20 7220 9795


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXGZGZLGDDGGZZ ]]>
TwitterFacebookLinkedIn